{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-264928","form_type":"8-K","ticker":"DNA","cik":"0001830214","company_name":"Ginkgo Bioworks Holdings, Inc.","filed_at":"2022-10-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.489424+00:00","generated_at":"2026-06-23T02:44:40.314129+00:00","sec_items":["2.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ginkgo Bioworks completes acquisition of Zymergen; exchange ratio 0.9179","bullets":["Acquisition closed on October 19, 2022, per the merger agreement signed July 24, 2022.","Zymergen stockholders received 0.9179 Ginkgo Class A shares per Zymergen share held.","Zymergen shares will cease trading on Nasdaq; Ginkgo common stock continues on NYSE as DNA.","Expected to enhance Ginkgo's platform with added automation, software, and biological engineering expertise."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-264928","json":"https://secwatch.observer/filing/0001193125-22-264928.json","markdown":"https://secwatch.observer/filing/0001193125-22-264928.md","text":"https://secwatch.observer/filing/0001193125-22-264928.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1830214/000119312522264928/0001193125-22-264928-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1830214/000119312522264928/d413226d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T02:44:40.314129+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}